Association of Anti–Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma
Open accessAbstract
This cohort study of patients with advanced melanoma treated with anti–programmed cell death 1 with or without ipilimumab assessed whether cutaneous toxic effects were associated with superior clinical outcomes.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Among advanced melanoma patients who developed dermatologic IRAEs, OS was superior to those who did not (1691 vs 526 days, p < .001).
“Among patients who developed dermatologic IRAEs, RR (60% vs 27%, p < .001), PFS (797 vs 112 days, p < .001) and OS (1691 vs 526 days, p < .001) were all superior to these measures in patients who did not develop dermatologic IRAEs.”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [53]
Among advanced melanoma patients who developed dermatologic IRAEs, RR was superior to those who did not (60% vs 27%, p < .001).
“Among patients who developed dermatologic IRAEs, RR (60% vs 27%, p < .001), PFS (797 vs 112 days, p < .001) and OS (1691 vs 526 days, p < .001) were all superior to these measures in patients who did not develop dermatologic IRAEs.”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [53]
Multivariate logistic regression, controlling for age, combination therapy, prior therapy and sex, confirmed an independent association of dermatologic IRAEs with superior RR (OR 3.58; 95% CI 2.17-5.90; p < .001).
“Multivariate logistic regression, controlling for age, combination therapy, prior therapy and sex, confirmed an independent association of dermatologic IRAEs with superior RR (OR 3.58; 95% CI 2.17–5.90; p < .001).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [53]
Among advanced melanoma patients who developed dermatologic IRAEs, PFS was superior to those who did not (797 vs 112 days, p < .001).
“Among patients who developed dermatologic IRAEs, RR (60% vs 27%, p < .001), PFS (797 vs 112 days, p < .001) and OS (1691 vs 526 days, p < .001) were all superior to these measures in patients who did not develop dermatologic IRAEs.”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158 · see citing works
Hua, C., Boussemart, L., Mateus, C., Routier, E., Boutros, C., Cazenave, H., Viollet, R., Thomas, M., Roy, S., Benannoune, N., et al. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.2707 · Cited by 655 · see citing works
Faje, A. T., Lawrence, D., Flaherty, K., Freedman, C., Fadden, R., Rubin, K., Cohen, J., & Sullivan, R. J. (2018) · Cancer · doi:10.1002/cncr.31629 · Cited by 486 · see citing works
Immune Checkpoint Inhibitor Toxicity in 2018
Johnson, D. B., Chandra, S., & Sosman, J. A. (2018) · JAMA · doi:10.1001/jama.2018.13995 · Cited by 239 · see citing works
Self-citationRichmond, J. M., Strassner, J. P., Rashighi, M., Agarwal, P., Garg, M., Essien, K. I., Pell, L., & Harris, J. E. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.10.032 · Cited by 152 · see citing works
Pruritus Associated with Targeted Anticancer Therapies and Their Management
Wu, J., & Lacouture, M. E. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.02.010 · Cited by 43 · see citing works
Richmond, J., Strassner, J. P., Rashighi, M., et al. (2018) · immuneACCESS · doi:10.21417/b7v884 · Cited by 11 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0805-8 · Cited by 1,145 · see citing works
Self-citationImmune-checkpoint inhibitors: long-term implications of toxicity
Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982 · see citing works
Self-citationDas, S., Ciombor, K. K., Haraldsdottir, S., Pumpalova, Y., Sahin, I. H., Pineda, G., Shyr, Y., Lin, E. P., Hsu, C.-Y., Chu, S.-K., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0637 · Cited by 41 · see citing works
- Authors
- Quach, H. T., Dewan, A. K., Davis, E. J., Ancell, K. K., Fan, R., Ye, F., & Johnson, D. B.
- Affiliations
- Vanderbilt University (US)
- Vanderbilt University Medical Center (US)
- Corresponding author
- Johnson, Douglas B.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-06-01
- Volume
- 5
- Issue
- 6
- Pages
- 906
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC6567826
- OpenAlex
- W2939940798
- Cited by
- 107
- References
- 7
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 13 · 2023: 11 · 2022: 16 · 2021: 25 · 2020: 22 · 2019: 7
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (K12CA090625)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- anti-PD-1 therapy, cutaneous adverse events, advanced melanoma, ipilimumab, immune checkpoint inhibitors, treatment toxicity, clinical outcomes, melanoma immunotherapy
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Adult, Aged, Aged, 80 and over, Drug Eruptions, Exanthema, Female, Humans, Male, Melanoma, Middle Aged, Pruritus, Retrospective Studies, Skin Neoplasms, Vitiligo, Treatment Outcome, Young Adult, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
